Background
Dane Fisher and Raghunath Lalgudi applied for a patent covering five expressed sequence tags (ESTs) — short nucleotide sequences representing fragments of messenger RNA transcribed from maize genes. ESTs are generated in large numbers by sequencing partial copies of genes expressed in particular tissues at particular times. The patent application sought to protect these specific EST sequences without having identified the biological functions of the corresponding full-length genes. The applicants asserted seven potential uses for their claimed ESTs: serving as molecular markers for genome mapping, measuring gene expression via microarrays, providing primers for PCR amplification, identifying polymorphisms, isolating gene promoters, controlling protein expression, and locating genetic molecules in other organisms.
The Patent and Trademark Office rejected the claims for lack of utility under 35 U.S.C. § 101, finding that the asserted uses were not specific and substantial utilities that would provide a real-world benefit justifying patent protection. The Board of Patent Appeals affirmed. Fisher and Lalgudi appealed to the Federal Circuit, arguing that their claimed ESTs had multiple demonstrated research uses and that molecular tools used in research are patentable subject matter.
The Court’s Holding
The Federal Circuit affirmed the rejection in an opinion by Judge Michel. The court applied the utility framework from the Supreme Court’s decision in Brenner v. Manson (1966), which requires that inventions have a specific and substantial utility — meaning a defined and real-world use that goes beyond merely being a starting point for further research.
The court found that the seven asserted uses of the claimed ESTs were all variations on the same generic research utility: finding out more information about the underlying genes. Each of the seven uses required further research and investigation before any concrete benefit could be realized. The ESTs were not themselves useful in treating a disease, improving a crop, or producing a product — they were research intermediates that might eventually lead to useful discoveries about gene function. This kind of general research utility is insufficient for patentability. Allowing patents on gene fragments whose functions are unknown would effectively allow patent holders to block research on entire biological pathways before the underlying science is understood.
The court also applied its precedent from Brenner and from In re Ziegler, holding that utilities that are merely “a starting point for further research” do not satisfy § 101. The fact that ESTs are technically useful research tools did not change this analysis — the issue was not whether the tools had any use, but whether they provided a specific, well-defined real-world benefit. Without knowing what the corresponding genes do, there was no such specific and substantial utility. Judge Rader dissented, arguing that the majority’s approach effectively imposed a higher utility standard on gene patents than on other kinds of inventions.
Key Takeaways
- The utility requirement under 35 U.S.C. § 101 requires “specific and substantial” utility — an invention must provide a specific, well-defined, real-world benefit, not merely serve as a starting point for further research to discover what benefits the invention might eventually provide.
- Expressed sequence tags and other gene fragments without identified biological function lack specific and substantial utility, even if they can be used as generic research tools in experiments that might eventually reveal the function of the corresponding genes.
- Generic research uses — such as serving as a molecular marker, providing a PCR primer, or enabling microarray analysis — are insufficient to establish patentable utility when all of these uses simply amount to different methods of investigating what the underlying genes do.
- The utility doctrine serves a policy function in genomics and biotechnology: allowing patents on gene fragments of unknown function would allow patent holders to block downstream research and invention across entire biological pathways before the science is understood.
- Biotechnology inventors claiming gene sequences or biological molecules should be prepared to demonstrate specific and substantial utility tied to a defined biological function or therapeutic, agricultural, or industrial application — not merely general research utility.
Why It Matters
In re Fisher is the Federal Circuit’s definitive ruling on the patentability of expressed sequence tags — a technology that was central to early genomics research in the 1990s and early 2000s. At the height of the human genome project and its aftermath, thousands of ESTs were generated as byproducts of large-scale gene sequencing, and significant questions arose about whether and how they could be patented. The Fisher decision resolved this question definitively: ESTs without identified gene function fail the utility requirement.
The case is significant beyond ESTs because it provides a framework for analyzing utility in any situation where a biological molecule is a research tool rather than a direct commercial or therapeutic agent. The court’s insistence on specific and substantial utility — rather than general research utility — shapes the patentability analysis for all early-stage biological discoveries. For the pharmaceutical and agricultural biotechnology industries, the case underscores that patent protection in genomics requires more than identification of a gene or sequence: inventors must understand what the gene does and demonstrate a concrete application of that knowledge. Judge Rader’s dissent previewed ongoing debates about whether utility doctrine is applied too stringently in the life sciences compared to other technology fields.